Results 271 to 280 of about 43,876 (313)

Donepezil for Alzheimer’s disease

Expert Review of Neurotherapeutics, 2007
Donepezil is the most widely prescribed of the cholinesterase inhibitors that has been licensed for the treatment of mild-to-moderate Alzheimer's disease. Evidence from a number of clinical trials suggests that it improves cognitive performance and stabilizes the functional abilities in people with mild-to-moderate Alzheimer's disease.
Boben Benjamin, Alistair Burns
openaire   +3 more sources

Spectroscopic, calorimetric and molecular docking insight into the interaction of Alzheimer’s drug donepezil with human transferrin: implications of Alzheimer’s drug

Journal of Biomolecular Structure and Dynamics, 2019
Donepezil, a highly selective and reversible inhibitor, is amongst the widely used drugs for the treatment of Alzheimer’s disease (AD) across the globe. Clinically significant human transferrin (hTf) is a key player involved in iron metabolism.
Anas Shamsi, Moyad Al Shahwan, Shahzaib Ahamad, M. Hassan, F. Ahmad, A. Islam   +5 more
semanticscholar   +1 more source

Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats

Fundamental & Clinical Pharmacology, 2020
Recent studies raise the possibility that donepezil can delay the progression of Alzheimer’s disease (AD). This research evaluated the efficacy of donepezil in an animal model with brain insulin resistance and AD‐like alterations. Rats were fed with high‐
A. Gomaa, Rania M. Makboul, M. El-Mokhtar, Engy A. Abdel‐Rahman, Israa A Ahmed, M. Nicola   +5 more
semanticscholar   +1 more source

Donepezil

PharmacoEconomics, 1999
Donepezil is a specific acetylcholinesterase inhibitor that can improve symptoms in patients with mild-to-moderate Alzheimer's disease; cognitive function is maintained above baseline levels for up to 1 year and normal decline of cognitive function is slowed.
Rachel H. Foster, Greg L. Plosker
openaire   +3 more sources

Understanding binding between donepezil and human ferritin: molecular docking and molecular dynamics simulation approach

Journal of Biomolecular Structure and Dynamics, 2020
Donepezil is an acetylcholinesterase inhibitor (AChEI) in use to treat symptomatic patients of mild to moderate Alzheimer’s disease (AD). Ferritin is an iron protein associated with storage and sequestration of excess ferrous iron in a way maintaining ...
Moyad Shahwan, M. Khan, F. Husain, Anas Shamsi   +3 more
semanticscholar   +1 more source

Microglia signaling as a target of donepezil

Neuropharmacology, 2010
Donepezil is a reversible and noncompetitive cholinesterase inhibitor. The drug is considered as a first-line treatment in patients with mild to moderate Alzheimer's disease. Recently, anti-inflammatory and neuroprotective effects of the drug have been reported. "Cholinergic anti-inflammation pathway" has major implications in these effects.
Jaegyu Hwang, Heehong Hwang, Kyoungho Suk, Ho-Won Lee   +3 more
openaire   +3 more sources

A Novel Formulation: Donepezil Patch

The Senior Care Pharmacist, 2023
Prevalence of dementia continues to increase with limited pharmacotherapy options available. Acetylcholinesterase inhibitors remain a mainstay of treatment. The US FDA has approved three oral medications within this class— donepezil, galantamine, and rivastigmine.
Megan, Adelman, Lora, Louis
openaire   +2 more sources

Donepezil Attenuates Obesity-Associated Oxidative Stress and Central Inflammation and Improves Memory Deficit in Mice Fed a High-Fat Diet

Dementia and Geriatric Cognitive Disorders, 2020
Background/Aims: Obesity is associated with chronic inflammation and cognitive decline, and is considered a major risk factor for neurodegeneration.
Luxia Jiang, Ying-ying Wang, Lingying Su, Huimin Ren, Cuiwei Wang, Jianzhong Chen, Xiaobing Fu   +6 more
semanticscholar   +1 more source

A 10-year perspective on donepezil

Expert Opinion on Pharmacotherapy, 2013
Donepezil is the first cholinesterase inhibitor widely used for the treatment of Alzheimer's disease (AD). Its pharmacological actions are straightforward, enhancing cholinergic activity both in the brain and systemically, with a long-enough half-life to allow for once a day dosing.
Serge Gauthier, Laksanun Cheewakriengkrai   +1 more
openaire   +2 more sources

DONEPEZIL-RELATED TOXIC HEPATITIS

Acta Clinica Belgica, 2008
Alzheimer's disease (AD) is the leading cause of dementia. It is characterized by the presence of senile plaques and neurofibrillary tangles in the brain, and impairment of the central cholinergic system, which contribute to memory loss and cognitive dysfunction.
Dierickx, R., Vandewoude, Maurits
openaire   +4 more sources